Cytosorbents Corp (CTSO) CFO Sells $236,520.00 in Stock

Cytosorbents Corp (NASDAQ:CTSO) CFO Kathleen P. Bloch sold 32,400 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $7.30, for a total transaction of $236,520.00. Following the sale, the chief financial officer now owns 248,638 shares of the company’s stock, valued at $1,815,057.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Cytosorbents Corp (NASDAQ CTSO) traded down $0.05 on Wednesday, hitting $7.35. 116,110 shares of the stock traded hands, compared to its average volume of 139,094. Cytosorbents Corp has a 12 month low of $3.30 and a 12 month high of $7.55. The company has a market capitalization of $210.88, a PE ratio of -19.34 and a beta of -0.54. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.36 and a quick ratio of 3.17.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wealthcare Advisory Partners LLC bought a new position in shares of Cytosorbents during the third quarter worth approximately $365,000. Fortaleza Asset Management Inc. increased its holdings in shares of Cytosorbents by 81.6% during the third quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock worth $145,000 after purchasing an additional 10,500 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Cytosorbents by 145.2% during the second quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after purchasing an additional 22,500 shares during the period. 8.65% of the stock is currently owned by institutional investors.

Several brokerages have issued reports on CTSO. ValuEngine upgraded shares of Cytosorbents from a “sell” rating to a “hold” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Cytosorbents in a research report on Tuesday. Maxim Group set a $12.00 price objective on shares of Cytosorbents and gave the stock a “buy” rating in a research report on Monday. Finally, B. Riley restated a “buy” rating and set a $11.25 price objective on shares of Cytosorbents in a research report on Friday, November 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Cytosorbents currently has an average rating of “Buy” and a consensus price target of $10.60.

TRADEMARK VIOLATION NOTICE: “Cytosorbents Corp (CTSO) CFO Sells $236,520.00 in Stock” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.themarketsdaily.com/2018/01/11/cytosorbents-corp-ctso-cfo-sells-236520-00-in-stock.html.

Cytosorbents Company Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Insider Buying and Selling by Quarter for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply